Key points from article :
Longevity industry can be divided into "longevity now" (e.g. selling biomarker tests & supplements) and "longevity next" (e.g. cellular reprogramming).
Longevity investment reached $3.01bn in 2023, down from the peak of $9.26bn in 2021.
The median deal size in longevity investment was $5.00mn in 2023.
During 2019-2023, Longevity Discovery Platforms attracted the most investment ($10.61bn), followed by Neuropharma ($6.27bn) and Cellular Reprogramming ($4.35bn).
Big Pharma is showing indirect interest in longevity (e.g. GLP-1s).
Longevity deals by quarter remained stable, averaging 48 deals per quarter.
“Longevity has yet to experience its AI moment,” commented report co-author, Phil Newman.
